SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Laurus Labs surges on getting approval from USFDA for TLD

04 Feb 2019 Evaluate

Laurus Labs is currently trading at Rs. 359.00, up by 6.55 points or 1.86% from its previous closing of Rs. 352.45 on the BSE.

The scrip opened at Rs. 371.00 and has touched a high and low of Rs. 371.00 and Rs. 351.00 respectively.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 548.55 on 14-Feb-2018 and a 52 week low of Rs. 330.30 on 26-Oct-2018.

Last one week high and low of the scrip stood at Rs. 375.00 and Rs. 351.00 respectively. The current market cap of the company is Rs. 3751.36 crore.

The promoters holding in the company stood at 33.50%, while Institutions and Non-Institutions held 46.38% and 20.13% respectively.

Laurus Labs has received tentative approval from United States Food and Drug Administration (USFDA) under PEPFAR for Tenofovir / Lamivudine / Dolutegravir (TLD) 300/300/50mg fixed dose combination (FDC).

The TLD product will be available in the Generic form in low and middle income countries (LMIC). TLD is the preferred treatment recommended by US department of Health and Human Services Panel and also WHO has recommended TLD as one of the preferred first line regimen for the treatment of people living with HIV.

The company expects to commercialise this important medicine in the access markets and the product will be manufactured from the company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

1126.50 -3.15 (-0.28%)
21-Apr-2026 10:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1225.70
Cipla 1232.80
Zydus Lifesciences 931.95
Lupin 2325.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×